217 related articles for article (PubMed ID: 7527876)
1. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy.
Gambaro G; Venturini AP; Noonan DM; Fries W; Re G; Garbisa S; Milanesi C; Pesarini A; Borsatti A; Marchi E
Kidney Int; 1994 Sep; 46(3):797-806. PubMed ID: 7527876
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats.
Gambaro G; Cavazzana AO; Luzi P; Piccoli A; Borsatti A; Crepaldi G; Marchi E; Venturini AP; Baggio B
Kidney Int; 1992 Aug; 42(2):285-91. PubMed ID: 1328749
[TBL] [Abstract][Full Text] [Related]
3. Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment.
Ceol M; Nerlich A; Baggio B; Anglani F; Sauer U; Schleicher E; Gambaro G
Lab Invest; 1996 Feb; 74(2):484-95. PubMed ID: 8780166
[TBL] [Abstract][Full Text] [Related]
4. Retention of glomerular basement membrane-proteoglycans accompanying loss of anionic site staining in experimental diabetes.
Templeton DM
Lab Invest; 1989 Aug; 61(2):202-11. PubMed ID: 2755078
[TBL] [Abstract][Full Text] [Related]
5. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.
van den Born J; van Kraats AA; Bakker MA; Assmann KJ; Dijkman HB; van der Laak JA; Berden JH
Diabetologia; 1995 Oct; 38(10):1169-75. PubMed ID: 8690168
[TBL] [Abstract][Full Text] [Related]
6. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate.
van den Born J; van Kraats AA; Bakker MA; Assmann KJ; van den Heuvel LP; Veerkamp JH; Berden JH
Diabetologia; 1995 Feb; 38(2):161-72. PubMed ID: 7713310
[TBL] [Abstract][Full Text] [Related]
7. Glomerular proteoglycans in diabetes. Partial structural characterization and metabolism of de novo synthesized heparan-35SO4 and dermatan-35SO4 proteoglycans in streptozocin-induced diabetic rats.
Klein DJ; Brown DM; Oegema TR
Diabetes; 1986 Oct; 35(10):1130-42. PubMed ID: 2944782
[TBL] [Abstract][Full Text] [Related]
8. The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy.
Gomes CL; Leão CL; Venturotti C; Barreira AL; Guimarães G; Fonseca RJ; Fortunato RS; Mourão PA; Delgado AG; Takiya CM; Leite M
PLoS One; 2014; 9(9):e106929. PubMed ID: 25192337
[TBL] [Abstract][Full Text] [Related]
9. Release of glomerular heparan-35SO4 proteoglycan by heparin from glomeruli of streptozocin-induced diabetic rats.
Klein DJ; Oegema TR; Brown DM
Diabetes; 1989 Jan; 38(1):130-9. PubMed ID: 2521210
[TBL] [Abstract][Full Text] [Related]
10. ECM gene expression and its modulation by insulin in diabetic rats.
Fukui M; Nakamura T; Ebihara I; Shirato I; Tomino Y; Koide H
Diabetes; 1992 Dec; 41(12):1520-7. PubMed ID: 1280237
[TBL] [Abstract][Full Text] [Related]
11. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats.
Reddi AS; Ramamurthi R; Miller M; Dhuper S; Lasker N
Biochem Med Metab Biol; 1991 Feb; 45(1):119-31. PubMed ID: 2015105
[TBL] [Abstract][Full Text] [Related]
12. Pathobiochemical aspects of diabetic nephropathy.
Schleicher E; Nerlich A; Gerbitz KD
Klin Wochenschr; 1988 Sep; 66(18):873-82. PubMed ID: 2972877
[TBL] [Abstract][Full Text] [Related]
13. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane.
Tamsma JT; van den Born J; Bruijn JA; Assmann KJ; Weening JJ; Berden JH; Wieslander J; Schrama E; Hermans J; Veerkamp JH
Diabetologia; 1994 Mar; 37(3):313-20. PubMed ID: 8174847
[TBL] [Abstract][Full Text] [Related]
14. Loss of glomerular anionic sites and the development of albuminuria in rats with streptozotocin-induced diabetes.
Moriya T; Nakazawa K; Itoh N; Shigematsu H; Okada N; Aizawa T; Yamada T; Yajima Y
Nephron; 1993; 65(3):444-8. PubMed ID: 8289997
[TBL] [Abstract][Full Text] [Related]
15. No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy.
van den Born J; Pisa B; Bakker MA; Celie JW; Straatman C; Thomas S; Viberti GC; Kjellen L; Berden JH
J Biol Chem; 2006 Oct; 281(40):29606-13. PubMed ID: 16885165
[TBL] [Abstract][Full Text] [Related]
16. Undersulfation of glomerular basement membrane heparan sulfate in experimental diabetes and lack of correction with aldose reductase inhibition.
Cohen MP; Klepser H; Wu VY
Diabetes; 1988 Oct; 37(10):1324-7. PubMed ID: 2970980
[TBL] [Abstract][Full Text] [Related]
17. Alterations of glomerular basement membrane charge and structure in diabetic nephropathy.
Goode NP; Shires M; Crellin DM; Aparicio SR; Davison AM
Diabetologia; 1995 Dec; 38(12):1455-65. PubMed ID: 8786020
[TBL] [Abstract][Full Text] [Related]
18. Proteoglycans and glycosaminoglycans synthesized in vitro by mesangial cells from normal and diabetic rats.
Hadad SJ; Michelacci YM; Schor N
Biochim Biophys Acta; 1996 May; 1290(1):18-28. PubMed ID: 8645702
[TBL] [Abstract][Full Text] [Related]
19. [Pentosan polysulfate sodium prevents kidney morphological changes and albuminuria in rats with type 1 diabetes].
Mathison Natera Y; Finol HJ; Quero Z; González R; González J
Nefrologia; 2010; 30(6):639-45. PubMed ID: 21113213
[TBL] [Abstract][Full Text] [Related]
20. Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats.
Bollineni JS; Alluru I; Reddi AS
Curr Eye Res; 1997 Feb; 16(2):127-30. PubMed ID: 9068943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
